NCT00833456

Brief Summary

The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary study objective is to compare general functioning of patients with schizophrenia treated with Seroquel SR between baseline and the last study visit. The secondary study objectives are to compare general functioning of patients with schizophrenia treated with other atypical antipsychotic medicinal products administered once daily between baseline and the last study visit, monitoring of other indicators of clinical improvement, evaluation of patient compliance and assessment of occurrence of adverse effects

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
106

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2009

Geographic Reach
1 country

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 29, 2009

Completed
3 days until next milestone

Study Start

First participant enrolled

February 1, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 2, 2009

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2010

Completed
Last Updated

October 14, 2011

Status Verified

October 1, 2011

Enrollment Period

1.7 years

First QC Date

January 29, 2009

Last Update Submit

October 13, 2011

Conditions

Keywords

schizophreniaSeroquel SRatypical antipsychoticsassessment of functioningGAF scale

Outcome Measures

Primary Outcomes (1)

  • To compare improvement in global assessment of functioning (using the GAF scale) between the baseline and the final study visit in the Seroquel SR-treated group.

    three times: 0, 12 and 24 weeks after inclusion

Secondary Outcomes (1)

  • To assess improvement in global assessment of functioning (using the GAF scale) between the baseline and the final study visit in the group of patients treated with other atypical antipsychotics

    three times: 0, 12 and 24 weeks after inclusion

Study Arms (2)

1

Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion

2

Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients visiting psychiatrist's practice

You may qualify if:

  • patients have a diagnosis of schizophrenia, as defined by DSM-IV-TR

You may not qualify if:

  • patients who are treated with Seroquel SR or other antipsychotic more than 1 month
  • patients with prescribed antipsychotic combinations
  • pregnant women or women who are breast-feeding
  • patients who have been treated with antipsychotics in depot formulations for the last two months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Research Site

Begunje na Gorenjskem, Slovenia

Location

Research Site

Brezovica pri Ljubljani, Slovenia

Location

Research Site

Brežice, Slovenia

Location

Research Site

Idrija, Slovenia

Location

Research Site

Koper, Slovenia

Location

Research Site

Ljubljana, Slovenia

Location

Research Site

Maribor, Slovenia

Location

Research Site

Nova Gorica, Slovenia

Location

Research Site

Novo Mesto, Slovenia

Location

Research Site

Ormož, Slovenia

Location

Research Site

Postojna, Slovenia

Location

Research Site

Radenci, Slovenia

Location

Research Site

Sežana, Slovenia

Location

Research Site

Vojnik, Slovenia

Location

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Peter Pregelj, MD, PhD

    Psihiatricna klinika Ljubljana, Studenec 48, 1260 Ljubljana

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 29, 2009

First Posted

February 2, 2009

Study Start

February 1, 2009

Primary Completion

November 1, 2010

Study Completion

November 1, 2010

Last Updated

October 14, 2011

Record last verified: 2011-10

Locations